Proteomics, Pathway Array and Signaling Network-Based Medicine in Cancer
David Y. Zhang,Fei Ye,Ling Gao,Xiaoliang Liu,Xin Zhao,Yufang Che,Hongxia Wang,Libo Wang,Josephine Wu,Dong Song,Wei Liu,Hong Xu,Bo Jiang,Weijia Zhang,Jinhua Wang,Peng Lee
DOI: https://doi.org/10.1186/1747-1028-4-20
2009-01-01
Cell Division
Abstract:Cancer is a multifaceted disease that results from dysregulated normal cellular signaling networks caused by genetic, genomic and epigenetic alterations at cell or tissue levels. Uncovering the underlying protein signaling network changes, including cell cycle gene networks in cancer, aids in understanding the molecular mechanism of carcinogenesis and identifies the characteristic signaling network signatures unique for different cancers and specific cancer subtypes. The identified signatures can be used for cancer diagnosis, prognosis, and personalized treatment. During the past several decades, the available technology to study signaling networks has significantly evolved to include such platforms as genomic microarray (expression array, SNP array, CGH array, etc.) and proteomic analysis, which globally assesses genetic, epigenetic, and proteomic alterations in cancer. In this review, we compared Pathway Array analysis with other proteomic approaches in analyzing protein network involved in cancer and its utility serving as cancer biomarkers in diagnosis, prognosis and therapeutic target identification. With the advent of bioinformatics, constructing high complexity signaling networks is possible. As the use of signaling network-based cancer diagnosis, prognosis and treatment is anticipated in the near future, medical and scientific communities should be prepared to apply these techniques to further enhance personalized medicine.